Clinical Trials
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0342
Phase II Selection Design Trial of Concurrent Chemotherapy + Cetuximab vs. Chemotherapy Followed by Cetuximab in Advanced Non-Small Cell Lung Cancer (NSCLC)
Research Committee(s)
Lung Cancer
Activated
07-01-2004
Closed
08-01-2005
Closed
Phase
Accrual
39%
Published
SWOG Clinical Trial Number
S0338
Phase II Trial of Imatinib Mesylate (Gleevec) (NSC-716051) In Combination With Capecitabine (Xeloda) (NSC-712807) In Metastatic Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06-15-2004
Closed
12-15-2005
Closed
Phase
Accrual
94%
Published
SWOG Clinical Trial Number
S0000C
Prevention of Lung Function Decline with Vitamin E and Selenium - Respiratory Ancillary Study (RAS) to SELECT
Research Committee(s)
Other
Activated
06-04-2004
Closed
05-01-2007
Closed
Phase
Accrual
20%
Published
SWOG Clinical Trial Number
S0345
A Phase II Study of Imatinib (NSC-716051) in Patients with Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans
Research Committee(s)
Sarcoma
Activated
05-15-2004
Closed
12-15-2006
Closed
Phase
Accrual
93%
Published
SWOG Clinical Trial Number
S0106
A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg�) Induction Therapy Versus Standard Induction With Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy With Gemtuzumab Ozogamicin (Mylotarg�) or No Additional Therapy for Patients Under Age 61 With Previously Untreated De Novo Acute Myeloid Leukemia (AML)
Research Committee(s)
Leukemia
Activated
05-15-2004
Closed
08-20-2009
Closed
Phase
Accrual
70%
Published
SWOG Clinical Trial Number
S0336
Phase II Trial of Depsipeptide (NSC-630176) in Colorectal Cancer Patients Who Have Received Either One or Two Chemotherapy Regimens for Metastatic or Locally Advanced, Unresectable Disease
Research Committee(s)
Gastrointestinal Cancer
Activated
04-15-2004
Closed
09-01-2005
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0226
Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer.
Status Notes
S0226 was completed on 10/1/2018. All patient follow-up has ended and the IND for this study was closed. Any remaining drug must be destroyed per institutional procedures and drug accountability records maintained per 21 CFR 312.62 and institutional procedures.
Research Committee(s)
Breast Cancer
Activated
04-01-2004
Closed
07-01-2009
Closed
Phase
Accrual
77%
Published
SWOG Clinical Trial Number
S0313
Evaluation of CHOP Plus Involved Field Radiotherapy followed by Yttrium-90 Ibritumomab Tiuxetan for Stages I, IE and non-bulky Stages II and IIE, CD20 Positive, High-risk Localized, Aggressive Histologies of Non-Hodgkin's Lymphoma, Phase II
Research Committee(s)
Lymphoma
Activated
02-01-2004
Closed
12-15-2008
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0339
"A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)."
Research Committee(s)
Lung Cancer
Activated
01-15-2004
Closed
10-01-2004
Closed
Phase
Accrual
95%
Published
SWOG Clinical Trial Number
S0115
A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m2) And Autologous Peripheral Blood Stem Cell Supported Transplantation (SCT) For Patients with AL Amyloidosis or High Risk (greater than or equal to Age 70 or Poor Renal Function)Patients With Multiple Myeloma(A BMT Study)
Research Committee(s)
Myeloma
Activated
01-01-2004
Closed
10-15-2010
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0205
A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
01-01-2004
Closed
04-01-2006
Closed
Phase
Accrual
60%
Published
SWOG Clinical Trial Number
S0330
U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II
Research Committee(s)
Sarcoma
Activated
12-15-2003
Closed
01-15-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0355
A Phase I Pharmacokinetic Study of Epothilone B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction.
Status Notes
S0355 was permanently closed to accrual on 8/15/2006. All patient follow-up for S0355 concluded on 12/17/2007, and S0355 was added to the SWOG no-follow list at that time.
Please retain records until at least April 30, 2022. If your site has not already done so, all CTEP-supplied Epothilone B Analog (BMS-247550) must be immediately returned to the NCI Clinical Repository at 627 Lofstrand Lane, Rockville, MD 20850 ATTN: RETURNS. FDA regulations require all remaining supplies of this agent to be returned to the IND sponsor.
Please retain records until at least April 30, 2022. If your site has not already done so, all CTEP-supplied Epothilone B Analog (BMS-247550) must be immediately returned to the NCI Clinical Repository at 627 Lofstrand Lane, Rockville, MD 20850 ATTN: RETURNS. FDA regulations require all remaining supplies of this agent to be returned to the IND sponsor.
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
11-01-2003
Closed
08-15-2006
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0221
"Phase III Trial of Continuous Schedule AC + G Vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High -Risk Node Negative Breast Cancer"
Status Notes
Effective immediately, the following S0221 Forms must be submitted in iMedidata RAVE: Follow-up Form, Supplemental Follow-up Form, S0221Trastuzumab Use Form, Notice of Death, Consent Withdrawal, and Lost to Follow-up. Rationale for change in data submission procedure, RAVE access, and data submission instructions are included in the 9/1/2020 memorandum, accessible from: www.ctsu.org.
Research Committee(s)
Breast Cancer
Activated
11-01-2003
Closed
01-15-2012
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0301
A Phase II Study of Induction With Daunorubicin, Cytarabine, and Cyclosporine All By Continuous IV Infusion for Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) in Patients of Age 56 or Older.
Research Committee(s)
Leukemia
Activated
10-01-2003
Closed
12-15-2006
Closed
Phase
Accrual
62%
Published
SWOG Clinical Trial Number
S0331
A Phase II Trial of STI-571/Imatinib (Gleevec®) (NSC-716051) in Neuroendocrine Carcinoma of the Skin (Merkel Cell Carcinoma)
Research Committee(s)
Melanoma
Activated
10-01-2003
Closed
03-01-2007
Closed
Phase
Accrual
56%
Published
SWOG Clinical Trial Number
S0230
Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer
Research Committee(s)
Breast Cancer
Cancer Survivorship
Activated
10-01-2003
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
S0202
A Phase II Trial of Gemcitabine (NSC-613327) and Capecitabine (NSC-712807) in Patients with Unresectable or Metastatic Gallbladder or Cholangiocarcinoma
Research Committee(s)
Gastrointestinal Cancer
Activated
09-01-2003
Closed
04-01-2005
Closed
Phase
Accrual
63%
Published
SWOG Clinical Trial Number
S0222
A Phase II Study of Tirapazamine (NSC-130181)/Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
Research Committee(s)
Lung Cancer
Activated
09-01-2003
Closed
07-24-2006
Closed
Phase
Accrual
75%
Published
SWOG Clinical Trial Number
S0327
A Phase II Trial of PS-341 (NSC-681239) in Patients with Platinum-Treated Extensive Stage Small Cell Lung Cancer.
Research Committee(s)
Lung Cancer
Activated
09-01-2003
Closed
09-15-2004